Evidence map›Paper›PMID 38665830›Full record

ArticleRSC medicinal chemistry2024

Nitrogen-containing andrographolide derivatives with multidrug resistance reversal effects in cancer cells.

Joana R L Ribeiro, Nikoletta Szemerédi, Bruno M F Gonçalves, Gabriella Spengler, Carlos A M Afonso, Maria-José U Ferreira

Open access · hybridAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Joana R L RibeiroResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa Av. Prof. Gama Pinto 1649-003 Lisbon Portugal mjuferreira@ff.ulisboa.pt.
Nikoletta SzemerédiDepartment of Medical Microbiology, Albert Szent-Györgyi Health Center, Albert Szent-Györgyi Medical School, University of Szeged Semmelweis utca 6 H-6725 Szeged Hungary.
Bruno M F GonçalvesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa Av. Prof. Gama Pinto 1649-003 Lisbon Portugal mjuferreira@ff.ulisboa.pt.ORCID https://orcid.org/0000-0002-3137-5329
Gabriella SpenglerDepartment of Medical Microbiology, Albert Szent-Györgyi Health Center, Albert Szent-Györgyi Medical School, University of Szeged Semmelweis utca 6 H-6725 Szeged Hungary.ORCID https://orcid.org/0000-0001-8085-0950
Carlos A M AfonsoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa Av. Prof. Gama Pinto 1649-003 Lisbon Portugal mjuferreira@ff.ulisboa.pt.ORCID https://orcid.org/0000-0002-7284-5948
Maria-José U FerreiraResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa Av. Prof. Gama Pinto 1649-003 Lisbon Portugal mjuferreira@ff.ulisboa.pt.ORCID https://orcid.org/0000-0002-8742-1486
University of Lisbon · PTUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) remains a challenging issue in cancer treatment. Aiming at finding anticancer agents to overcome MDR, the triacetyl derivative (2) of the labdane diterpenoid lactone andrographolide (1) underwent the Michael-type addition reaction followed by elimination, yielding twenty-three new derivatives, bearing nitrogen-containing substituents (3-25). Their structures were assigned, mainly, by 1D and 2D NMR experiments. The MDR reversal potential of compounds 1-25 was assessed, by functional and chemosensitivity assays, using resistant human

Identifiers

PMID38665830
PMCPMC11042158
OpenAlexW4392154077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.